伊立替康联合卡培他滨治疗晚期胃癌疗效分析

The Analysis of Curative Efficacy of Irinotecan Combined with Capecitabine in the Treatment of Advanced Gastric Cancer

目的观察伊立替康联合卡培他滨治疗晚期胃癌的疗效和毒副反应。方法全组24例胃癌均接受化疗。具体方案:伊立替康180 mg/m2,静脉滴注,d1;卡培他滨1 650 mg/(m2.d),口服,d1～5。14 d为l个周期,4个周期后评价疗效和毒副反应。结果全组24例中,CR 1例,PR 8例,SD 7例,PD 8例,总有效率为37.5%,疾病控制率为66.7%。中位疾病进展时间5.8个月,中位生存时间10.6个月。主要毒副反应为迟发性腹泻、骨髓抑制和恶心呕吐。结论伊立替康联合卡培他滨治疗胃癌疗效尚可,毒副反应可耐受。

Objective To investigate the efficacy and toxicities of irinotecan combined with capecitabine in the treatment of patients with advanced gastric cancer. Methods All the 24 patients received the chemotherapy. The regimen：irinotecan 180 mg/m2, dj ; capecitabine 1 650 rng/（m2 ~ d） ,dl.5. Every 14 days were 1 cycle. The efficacy and toxieities were evaluated after 4 cycles of chemotherapy. Results Among the 26 cases,CR l case,PR 8 eases,SD 7 cases,PD 8 cases,the total effective rate was 37.5% ,the disease control rate was 66.7%. The median time to progression was 5.8 months, the median survival time was 10.6 months. The main toxicities were delayed diarrhea, myelosuppres- sion, nausea and vomiting. Conclusion The irinoteean and capecitabine can be effective for the patients with advanced gastric cancer. Its toxicities can be tolerated.